Acquired Perforating Dermatosis (APD)
Acquired perforating dermatosis (APD) is a group of chronic skin conditions defined by an unusual biological event: transepidermal elimination, in which components of the dermal extracellular matrix (collagen fibers, elastic fibers or both) are pushed out through the epidermis. Unlike the inherited perforating disorders that begin in childhood, APD appears only in adults and is closely tied to serious systemic metabolic disease.
At its core, APD is a chain reaction that starts with microvascular ischemia and the build-up of toxic metabolic products (such as uric acid, calcium or uremic toxins) in the upper dermis. This sets off local inflammation that alters the collagen or elastin bundles and leads to their necrobiosis. In response, the overlying epidermis proliferates, sending down elongated rete ridges that surround the damaged tissue, then "perforates" to form a central channel through which the keratin and degenerated fibers are expelled onto the skin surface.
At Haute-Derma, we see APD as an internal "red alert" showing up on the skin. Perforating papules are a sign that the body's main filtering organs (kidneys, liver) or its vascular and metabolic systems are under serious strain, and they call for comprehensive care that closely links dermatology with internal medicine.
Links to Internal Disease and Clinical Settings
In clinical practice, APD almost always accompanies serious underlying medical illness. At Haute-Derma, we focus on tracing three main groups of causes:
End-Stage Chronic Kidney Disease (CKD / ESRD)
This is the most common association, often called uremic perforating dermatosis.
- It affects roughly 5% to 10% of patients on maintenance hemodialysis or peritoneal dialysis. Accumulated uremic toxins cause intense itching, and the resulting scratching creates micro-injuries (the Koebner phenomenon) that speed up transepidermal elimination of fibers.
Diabetes Mellitus (Type 1 and Type 2)
- Chronically high blood sugar produces advanced glycation end products (AGEs) on collagen fibers, changing the skin's protein structure so the fibers become brittle, break easily and degenerate. At the same time, diabetic microvascular disease reduces blood supply to the skin, allowing fiber necrosis to progress silently.
Other Associated Systemic Disorders
- APD can also arise in patients with cirrhosis, chronic liver failure, lymphoid malignancies or thyroid dysfunction.
How We Diagnose Acquired Perforating Dermatosis at Haute-Derma
To identify exactly which fibers are being eliminated and rule out ordinary nodular conditions, we follow a standard diagnostic pathway at Haute-Derma:
Recognizing the Characteristic Lesions
- Papule appearance: Dome-shaped papules or nodules 2 mm to 1 cm across, reddish-brown or dark gray-brown. They mainly affect the extensor surfaces of the limbs (forearms, shins), the thighs, shoulders and back.
- Central keratotic plug: The key feature is a firmly attached gray-white or cheesy keratin plug in the center of each papule. Forcing it out leaves a deep, bowl-shaped, bleeding ulcer.
Skin Biopsy and Special Stains (Gold Standard)
A punch biopsy is taken through the center of a perforating papule, including some normal skin at its edge.
- Histopathology (H&E): A channel or cup-shaped depression runs through the epidermis. It is filled with keratinized material, degenerating neutrophils and fragments of altered dermal fibers.
- Fiber-specific stains:
- Masson's trichrome: Shows green-stained collagen fibers lined up vertically along the channel on their way out (suggesting reactive perforating collagenosis, RPC).
- Verhoeff-Van Gieson (VVG): Shows black, fragmented elastic fibers being eliminated through the epidermis (suggesting elastosis perforans serpiginosa, EPS).
Blood Tests to Assess Internal Organs
- Required tests: blood glucose, HbA1c, creatinine, urea, estimated glomerular filtration rate (eGFR), and liver function (AST, ALT, bilirubin) to fully assess underlying organ dysfunction.
How the Condition Is Treated at Haute-Derma
Our treatment of APD at Haute-Derma rests on one principle: break the itch–scratch cycle from the outside while stabilizing metabolism from the inside.
Coordinated Medical Management (Essential)
- Tight blood sugar control to slow collagen glycation.
- Working with nephrologists to optimize dialysis, using high-performance membranes to clear as many uremic toxins from the circulation as possible and so reduce the root cause of the internal itch.
Topical Treatment for Itch and Inflammation
- Topical agents that regulate keratinization: Topical retinoids (such as tretinoin or tazarotene) normalize keratinocyte differentiation and loosen the central keratin plug, helping the necrotic material clear gently and preventing new plugged papules.
- High-potency corticosteroids: Applied under occlusion or micro-injected into the base of large, firm papules to quiet dermal inflammation, reduce swelling and relieve itching and stinging quickly.
Whole-Body Phototherapy
- Narrowband UVB (311 nm): The leading option for APD patients with itch due to kidney failure or diabetes. NB-UVB suppresses the release of inflammatory cytokines by keratinocytes and dampens the itch-sensing nerve fibers in the epidermis, so existing papules settle faster and scratching no longer creates new ones.
Laser Resurfacing
- Once inflammation and perforation are under control with phototherapy and medical care, the remaining pitted ulcers and dark scars are treated with fractional CO2 laser. The micro-beams break down rough fibrous scar tissue and stimulate healthy new collagen, restoring smoother skin.
